On fifth anniversary of partnership, Lundbeck
announces five-year commitment to Venezuelan clinic that is vital
to the Huntington’s disease community
Today, Lundbeck and the Hereditary Disease Foundation announced
the launch of the fifth annual Build Hope for Huntington’s Disease
(HD) initiative. The online donation campaign helps support the
Casa Hogar Corea de Huntington Amor y Fe (Huntington’s Chorea Home
of Love and Faith). This clinic provides care for the Venezuelan
families who were essential in leading to groundbreaking
discoveries in HD and other genetic diseases. To prompt a donation
from Lundbeck, visit www.BuildHopeforHD.com or www.hdfoundation.org
and click on the campaign icon. For every click before the end of
the year, Lundbeck will donate $15 to the clinic, up to
$25,000.
“For the past four years, Lundbeck has generously supported the
Casa Hogar, which is so crucial to the Venezuelan families with
Huntington's disease. These Venezuelan families helped find the
Huntington's disease gene,” said Nancy Wexler, Ph.D., President of
the Hereditary Disease Foundation and Higgins Professor of
Neuropsychology, Columbia University. “Each year, Lundbeck’s
support helps sustain them at a critical moment in time. Lundbeck
has provided over $260,000 since the campaign’s inception four
years ago. This generous support has sustained the clinic and
allowed it to continue serving the local HD community.”
To celebrate the fifth anniversary of Lundbeck’s partnership
with the Hereditary Disease Foundation, Lundbeck is also announcing
an additional five years of support for the Casa Hogar clinic
through Build Hope for HD.
“Through the Build Hope for HD campaign, Lundbeck has had the
privilege of giving back to the Venezuelan HD families who have
played such a critical role in advancing our understanding of HD
and genetic research,” said Raimonds Dzelme, Senior Director of
Movement Disorders Marketing of Lundbeck in the United States. “We
are absolutely thrilled to announce our support of this important
campaign for another five years as part of our long-term commitment
to the HD community. As research continues and progress is made, we
look forward to contributing to future advancements and ultimately
a cure that will help bring hope to the families who are affected
by this devastating disease.”
The Casa Hogar clinic opened in 1999 after a decade of
collaboration between the Hereditary Disease Foundation and local
Venezuelan authorities. The Casa Hogar provides free general and
HD-specific medical treatments, food, care and an integrated
nursing home to thousands of family members with HD who live along
the shores of Lake Maracaibo. The clinic serves as a model for best
care practices in the HD community, despite challenges of poverty
in the area. The Hereditary Disease Foundation has supported the
costs associated with the clinic for fifteen years, including
medical care, supplies, salaries and other expenses.
“Thanks to the families living around the shores of Lake
Maracaibo, we located the HD gene in 1983 and found the gene itself
in 1993,”1,2 said Wexler. “These extraordinary family members
revolutionize HD research and forever changed the lives of people
living with HD around the world. The Casa Hogar opened to pay
tribute to the sacrifices made by these families. It is crucial to
support this community and work together to find a cure for HD!
This is within our grasp! Your support makes the next discovery
possible.”
To learn more about the clinic and how much each click matters,
visit the Moving Together for HD Facebook page or the Hereditary
Disease Foundation’s website (www.hdfoundation.org).
About Huntington’s
Disease
Huntington’s disease is a hereditary neurodegenerative disease
characterized by a triad of behavioral, cognitive and motor
symptoms.3 These symptoms vary from person to person. The duration
of the disease after the onset of symptoms can range from 10 to 30
years4 and currently there is no cure.4 The HD gene’s mutation,
which results in the disease, was localized in 1983 and isolated in
1993.1,2 For more information on HD, please visit the Hereditary
Disease Foundation website (www.hdfoundation.org).
About the Hereditary Disease
Foundation
The Hereditary Disease Foundation aims to cure Huntington’s
disease (HD) by supporting research aimed at developing new
treatments and cures. The Hereditary Disease Foundation was started
by Dr. Milton Wexler in 1968 when his wife was diagnosed with
Huntington's disease. The Foundation uses a variety of strategies –
workshops, grants, fellowships, and targeted research contracts –
to solve the mysteries of genetic disease and develop new
treatments and cures. The Hereditary Disease Foundation initiated
the International-Venezuela Huntington’s Disease Collaborative
Research Project and played a key role in the discovery of the HD
gene, which was localized in 1983 and isolated in 1993.1,2 For more
information, visit the Hereditary Disease Foundation website
(www.hdfoundation.org).
About Lundbeck in the
U.S.
Based in Deerfield, Ill., Lundbeck U.S. was formed in 2009 as a
wholly-owned subsidiary of H. Lundbeck A/S in Denmark. With a focus
on accelerating advances in brain disorders, employees are engaged
in the research, development, production, marketing and sale of
innovative therapies that fulfill unmet medical needs among people
living with challenging and sometimes rare neurologic and
psychiatric disorders. In its late-stage research pipeline, the
company has neurology compounds under investigation for Alzheimer’s
disease, stroke and epilepsy, in addition to therapies in
development for mental health disorders. With a special commitment
to the lives of patients, families and caregivers, Lundbeck
actively engages in hundreds of initiatives each year that support
our patient communities. To learn more, visit us at
www.LundbeckUS.com and connect with us on Twitter at
@LundbeckUS.
About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global
pharmaceutical company specialized in brain diseases. For more than
50 years, we have been at the forefront of research within
neuroscience. Our development and distribution of pioneering
treatments continues to make a difference to people living with
brain diseases. Our key areas of focus are alcohol dependence,
Alzheimer’s disease, depression/anxiety, epilepsy, Huntington’s
disease, Parkinson’s disease, schizophrenia and stroke.
Our approximately 6,000 employees in 57 countries are engaged in
the entire value chain throughout research, development,
production, marketing and sales, and are committed to helping
people living with brain diseases. Our pipeline consists of several
late-stage development programs and our products are available in
more than 100 countries. We have research centers in China, Denmark
and the United States, and production facilities in China, Denmark,
France, Italy and Mexico. Lundbeck generated revenue of DKK 15.3
billion in 2013 (EUR 2.0 billion; USD 2.7 billion).
Lundbeck’s shares are listed on the stock exchange in Copenhagen
under the symbol “LUN”. Lundbeck has a sponsored Level 1 ADR
program listed in the US (OTC) under the symbol “HLUYY”. For
additional information, we encourage you to visit our corporate
site www.lundbeck.com.
References
- Gusella J, Wexler N, Conneally PM,
Naylor S, Anderson M, Tanzi R, Watkins PC, Ottina K, Wallace M,
Sakguchi A, Young AB, Shoulson I, Bonilla E, Martin JB. A
polymorphic DNA marker genetically linked to Huntington’s disease.
Nature 1983; 306:234-238.
- Huntington’s Disease Collaborative
Research Group. A novel gene containing a trinucleotide repeat that
is expanded and unstable on Huntington’s disease chromosomes. Cell
1993; 72:971-983.
- Marshall FJ, Clinical Features and
Treatment of Huntington’s Disease. Movement Disorders 2004;
1:589-596.
- Huntington’s Disease. Mayo Clinic.
http://www.mayoclinic.com/health/huntingtons-disease/DS00401/METHOD=print.
Last accessed 9/8/14.
UBR-D-00182 10/2014
LundbeckRachel Vann, 847-282-1139
H Lundbeck AS (PK) (USOTC:HLUYY)
Historical Stock Chart
From May 2024 to Jun 2024
H Lundbeck AS (PK) (USOTC:HLUYY)
Historical Stock Chart
From Jun 2023 to Jun 2024